ArticleDisease markers2014
Urine annexin A1 as an index for glomerular injury in patients.
Article in Disease markers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure.Journal of cardiac failure · 2020Trial
- Integrative Analysis on the Urinary Proteome of Diabetic Kidney Disease, with an Emphasis on Extracellular Matrix Proteins.International journal of molecular sciences · 2026Article
- ANXA1-mediated mTOR/FABP4 Inhibition Drives Antifibrotic Macrophage Reprogramming in Lupus Nephritis.International journal of biological sciences · 2026Article
- Annexin A1 expression in Lupus Nephritis.La Tunisie medicale · 2024Article
- The intricate role of annexin A2 in kidney: a comprehensive review.Renal failure · 2023Review
- Annexin-A1: The culprit or the solution?Immunology · 2022Review
- Annexin A1 and its receptor gene polymorphisms in systemic lupus erythematosus in the Tunisian population.Clinical rheumatology · 2022Article
- Renal Expression of Annexin A1 Is Associated With the Severity of Renal Injury in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.Frontiers in medicine · 2022Article
- Annexin A1 exerts renoprotective effects in experimental crescentic glomerulonephritis.Frontiers in physiology · 2022Article
- Review
- Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy.Kidney international · 2021Article
- Annexin-A1: Therapeutic Potential in Microvascular Disease.Frontiers in immunology · 2019Review
- Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria.Oncotarget · 2017Article
- Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.Experimental biology and medicine (Maywood, N.J.) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe recently demonstrated high urine levels of annexin A1 (ANXA1) protein in a mouse Adriamycin-induced glomerulopathy (ADG) model.
objectiveTo establish ANXA1 as a potential biomarker for glomerular injury in patients.
methodsA time-course study in the mouse ADG model, followed by renal tissues and urine samples from patients with various types of glomerular disorders for ANXA1.
resultsUrinary ANXA1 protein was (1) detectable in both the ADG model and in patients except those with minimal change disease (MCD); (2) positively correlated with renal lesions in patients; and (3) early detectable in diabetes patients with normoalbuminuria.
conclusionsANXA1 is a universal biomarker that is helpful in the early diagnosis, prognostic prediction, and outcome monitoring of glomerular injury. Measurement of urinary ANXA1 protein levels can help in differentiating MCD from other types of glomerular disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.